Advertisement

AAPS PharmSciTech

, Volume 19, Issue 7, pp 3067–3075 | Cite as

Preparation of Sustained Release Tablet with Minimized Usage of Glyceryl Behenate Using Post-Heating Method

  • Changmin Kang
  • Ju-Hyun Lee
  • Dong-Wook Kim
  • Beom-Jin Lee
  • Jun-Bom Park
Research Article

Abstract

The purpose of this study was to prepare sustained release (SR) matrix tablets using a direct compression incorporated with a post-heating process. Allopurinol was selected due to the water-soluble property and Compritol 888 ATO® (also known as glyceryl behenate) was used as an SR matrix-forming agent. The API, SR material, microcrystalline cellulose, and magnesium stearate (lubricant) were mixed and prepared into a tablet by a direct compression method. The compressed tablets were stored in a dry oven at four temperatures (60, 70, 80, and 90°C) and for three time periods (15, 30, 45 min). The DSC and PXRD data indicated that the crystallinity of the API was not altered by the post-heating method. However, SEM images demonstrated that Compritol 888 ATO® was melted by the post-heating method, and that the melted Compritol 888 ATO® could form a strong matrix. This strong matrix led to the significant sustained release behavior of hydrophilic APIs. As little as 3 mg of Compritol 888 ATO® (0.65% of total tablet weight), when heated at 80°C for 15 min, showed sustained release over 10 h. The post-heating method exerted a significant influence on lipid-based matrix tablets and allowed a reduction in the amount of material required for a water-soluble drug. This will also provide a valuable insight into lipid-based SR tablets and will allow their application to higher quality products and easier processing procedures.

KEY WORDS

post-heating glyceryl behenate sustained release direct compression dry oven 

Notes

Acknowledgments

This work was supported by the Sahmyook University Research Fund in 2016 (no. RI22016007).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  1. 1.
    Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. Pharm Sci Technolo Today. 2000;3:198–204.CrossRefGoogle Scholar
  2. 2.
    Jiménez-Martínez I, Quirino-Barreda T, Villafuerte-Robles L. Sustained delivery of captopril from floating matrix tablets. Int J Pharm. 2008;362:37–43.CrossRefGoogle Scholar
  3. 3.
    Viridén A, Abrahmsén-Alami S, Wittgren B, Larsson A. Release of theophylline and carbamazepine from matrix tablets—consequences of HPMC chemical heterogeneity. Eur J Pharm Biopharm. 2011;78:470–9.CrossRefGoogle Scholar
  4. 4.
    Li L, Wang L, Shao Y, Tian Y, Li C, Li Y, et al. Elucidation of release characteristics of highly soluble drug trimetazidine hydrochloride from chitosan–carrageenan matrix tablets. J Pharm Sci. 2013;102:2644–54.CrossRefGoogle Scholar
  5. 5.
    Peppas N, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50:27–46.CrossRefGoogle Scholar
  6. 6.
    Barthelemy P, Laforet J, Farah N, Joachim J. Compritol® 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm. 1999;47:87–90.CrossRefGoogle Scholar
  7. 7.
    Jeong KH, Woo HS, Kim CJ, Lee KH, Jeon JY, Lee SY, et al. Formulation of a modified-release pregabalin tablet using hot-melt coating with glyceryl behenate. Int J Pharm. 2015;495:1–8.CrossRefGoogle Scholar
  8. 8.
    Rosiaux Y, Jannin V, Hughes S, Marchaud D. Solid lipid excipients—matrix agents for sustained drug delivery. J Control Release. 2014;188:18–30.CrossRefGoogle Scholar
  9. 9.
    Saraiya D, Bolton S. The use of Precirol® to prepare sustained release tablets of theophylline and quinidine gluconate. Drug Dev Ind Pharm. 1990;16:1963–9.CrossRefGoogle Scholar
  10. 10.
    Özyazıcı M, Gökçe EH, Ertan G. Release and diffusional modeling of metronidazole lipid matrices. Eur J Pharm Biopharm. 2006;63:331–9.CrossRefGoogle Scholar
  11. 11.
    Anbalagan P, Liew CV, Heng PWS. Role of dwell on compact deformation during tableting: an overview. J Pharm Investig. 2017;47:173–81.CrossRefGoogle Scholar
  12. 12.
    Li F-Q, Hu J-H, Deng J-X, Su H, Xu S, Liu J-Y. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets. Int J Pharm. 2006;324:152–7.CrossRefGoogle Scholar
  13. 13.
    Schroeder H, Dakkuri A, Deluca P. Sustained release from inert wax matrixes I: drug–wax combinations. J Pharm Sci. 1978;67:350–3.CrossRefGoogle Scholar
  14. 14.
    Smith, A., Datta, S.P., Smith, G.H., Campbell, P.N., Bentley, R., McKenzie, H. Oxford dictionary of biochemistry and molecular biology, 2nd ed. Oxford: Oxford University Press; 2000.Google Scholar
  15. 15.
    Weiner, A. Lipid excipient for nasal delivery and topical application. US5200393A; 1993.Google Scholar
  16. 16.
    Thapa RK, Choi H-G, Kim JO, Yong CS. Analysis and optimization of drug solubility to improve pharmacokinetics. J Pharm Investig. 2017;47:95–110.CrossRefGoogle Scholar
  17. 17.
    Keen JM, Foley CJ, Hughey JR, Bennett RC, Jannin V, Rosiaux Y, et al. Continuous twin screw melt granulation of glyceryl behenate: development of controlled release tramadol hydrochloride tablets for improved safety. Int J Pharm. 2015;487:72–80.CrossRefGoogle Scholar
  18. 18.
    Hwang I, Kang C-Y, Park J-B. Advances in hot-melt extrusion technology toward pharmaceutical objectives. J Pharm Investig. 2017;47:123–32.CrossRefGoogle Scholar
  19. 19.
    Obaidat AA, Obaidat RM. Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate. Eur J Pharm Biopharm. 2001;52:231–5.CrossRefGoogle Scholar
  20. 20.
    Lee Y, Kim K, Kim M, Choi DH, Jeong SH. Orally disintegrating films focusing on formulation, manufacturing process, and characterization. J Pharm Investig. 2017;47:183–01.CrossRefGoogle Scholar
  21. 21.
    Rao M, Ranpise A, Borate S, Thanki K. Mechanistic evaluation of the effect of sintering on Compritol® 888 ATO matrices. AAPS PharmSciTech. 2009;10:355–60.CrossRefGoogle Scholar
  22. 22.
    Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265–78.CrossRefGoogle Scholar
  23. 23.
    Food and Drug Administration, Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration, Rockville, MD. 2000.Google Scholar
  24. 24.
    Emmerson BT. The management of gout. N Engl J Med. 1996;334:445–51.CrossRefGoogle Scholar
  25. 25.
    Roberts M, Pulcini L, Mostafa S, Cuppok-Rosiaux Y, Marchaud D. Preparation and characterization of Compritol 888 ATO matrix tablets for the sustained release of diclofenac sodium. Pharm Dev Technol. 2015;20(4):507–12.CrossRefGoogle Scholar
  26. 26.
    Brubach J, Jannin V, Mahler B, Bourgaux C, Lessieur P, Roy P, et al. Structural and thermal characterization of glyceryl behenate by X-ray diffraction coupled to differential calorimetry and infrared spectroscopy. Int J Pharm. 2007;336:248–56.CrossRefGoogle Scholar
  27. 27.
    Krajacic A, Tucker IG. Matrix formation in sustained release tablets: possible mechanism of dose dumping. Int J Pharm. 2003;251:67–78.CrossRefGoogle Scholar
  28. 28.
    Omelczuk MO, McGinity JW. The influence of thermal treatment on the physical–mechanical and dissolution properties of tablets containing poly (DL-lactic acid). Pharm Res. 1993;10:542–8.CrossRefGoogle Scholar
  29. 29.
    Patere SN, Desai NS, Jain AS, Kadam PP, Thatte UM, Gogtay N, et al. Compritol® 888 ATO a lipid excipient for sustained release of highly water soluble active: formulation, scale-up and IVIVC study. Curr Drug Deliv. 2013;10:548–56.CrossRefGoogle Scholar
  30. 30.
    El-Wahed MA, Refat M, El-Megharbel S. Metal complexes of antiuralethic drug: synthesis, spectroscopic characterization and thermal study on allopurinol complexes. J Mol Struct. 2008;888:416–29.CrossRefGoogle Scholar
  31. 31.
    Kaur A, Goindi S, Katare OP. Thermal analysis and quantitative characterization of compatibility between diflunisal and lipid excipients as raw materials for development of solid lipid nanoparticles. Thermochim Acta. 2016;643:23–32.CrossRefGoogle Scholar
  32. 32.
    Obaidat, R., Alnaief, M., and Mashaqbeh, H. Investigation of carrageenan aerogel microparticles as a potential drug carrier. AAPS PharmSciTech 2018;19(1):36–47.CrossRefGoogle Scholar
  33. 33.
    Patil A, Bjide S, Bookwala M, Soneta B, Shankar V, Almotairy A, et al. Stability of organoleptic agents in pharmaceuticals and cosmetics. AAPS PharmSciTech. 2018;19(1):36–47.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  1. 1.College of PharmacySahmyook UniversitySeoulRepublic of Korea
  2. 2.Department of Pharmaceutical EngineeringCheongju UniversityCheongjuRepublic of Korea
  3. 3.College of PharmacyAjou UniversitySuwonRepublic of Korea
  4. 4.Bioavailability Control LabSahmyook UniversitySeoulRepublic of Korea

Personalised recommendations